PMVP
PMV Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+75/100
Last price
1.61
▼ 0.17 (9.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.83
Prev close
1.78
Day high
1.81
Day low
1.59
Volume
616.10K
Market cap
$121.58M
P/E (TTM)
—
52W range
1.02 – 1.91
Day trading desk
Gap from prior close
+2.59%
Prior close 1.78
VWAP
1.67
-3.42% from price
Relative volume
0.92×
Normal
Session range
15.67%
1.59 – 1.84
Position in range
8%
Near session low
ATR (14D)
0.14
8.74% of price
Prior day high
1.84
PDH
Prior day low
1.70
PDL
Bid / ask spread
—
Quote not published
Session volume
599.29K
Avg 652.89K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+12.59%
+10.6%
1M
+24.81%
+23.7%
3M
+28.80%
+24.3%
6M
+24.81%
+6.6%
YTD
+28.80%
+14.6%
1Y
+11.81%
-4.6%
3Y
-73.78%
-156.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PMVP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 27, 25 | MACK DAVID HENRY Chief Executive Officer |
CONVERSION | 220.64K | $302.28K | Direct |
| Oct 23, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.00M | $1.52M | Indirect |
| Sep 10, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 500.00K | $635.00K | Indirect |
| Jul 1, 25 | MACK DAVID HENRY Chief Executive Officer |
SELL | 58.41K | $62.18K | Direct |
| Jul 1, 25 | TICKTIN ROBERT Chief Operating Officer |
SELL | 23.15K | $24.65K | Direct |
| Jul 1, 25 | JALOTA DEEPIKA Officer |
SELL | 33.06K | $35.20K | Direct |
| Jul 1, 25 | CARULLI MICHAEL Chief Financial Officer |
SELL | 28.25K | $30.08K | Direct |
| Jan 3, 25 | MACK DAVID HENRY Chief Executive Officer |
CONVERSION | 109.46K | $58.01K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARULLI MICHAEL |
Chief Financial Officer | 60.15K | Sale |
JALOTA DEEPIKA |
Officer | 89.96K | Sale |
MACK DAVID HENRY |
Chief Executive Officer | 1.13M | Conversion of Exercise of derivative security |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
TICKTIN ROBERT |
Chief Operating Officer | 98.69K | Sale |
Fundamentals
Market cap$121.58M
Enterprise value$6.85M
Revenue (TTM)—
Gross profit—
EBITDA$-79.54M
Net income$-75.22M
EPS (TTM)$-1.42
Free cash flow$-43.82M
Total cash$79.43M
Total debt$217.00K
Book value / share$1.34
Shares outstanding75.51M
Float43.29M
Short % of float3.96%
Dividend yield0.00%
Beta (5Y)1.35
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.67
PEG ratio—
Price / sales—
Price / book1.20
EV / revenue—
EV / EBITDA-0.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-70.93%
Return on assets-42.39%
Debt / equity0.30
Current ratio7.70
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $69.88M | $58.53M | $55.88M | $51.99M | +19.4% |
| Selling, general & admin | $16.33M | $26.92M | $24.25M | $25.05M | -39.3% |
| Total operating expense | $86.21M | $85.45M | $80.13M | $77.04M | +0.9% |
| Operating income | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -0.9% |
| Net interest income | $6.34M | $10.65M | $11.17M | $3.63M | -40.5% |
| Pre-tax income | -$79.91M | -$74.81M | -$68.96M | -$73.33M | -6.8% |
| Tax provision | -$2.17M | -$16.10M | $2.00K | -$9.00K | +86.5% |
| Net income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -32.4% |
| Net income to common | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -32.4% |
| Basic EPS | -1.48 | -1.14 | -1.44 | -1.61 | -29.8% |
| Diluted EPS | -1.48 | -1.14 | -1.44 | -1.61 | -29.8% |
| EBIT | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -0.9% |
| EBITDA | -$86.07M | -$84.30M | -$78.88M | -$76.72M | -2.1% |
| Basic shares | 52.54M | 51.58M | 48.01M | 45.59M | +1.9% |
| Diluted shares | 52.54M | 51.58M | 48.01M | 45.59M | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $37.98M | $40.88M | $37.71M | $108.30M | -7.1% |
| Cash & short-term investments | $112.94M | $169.45M | $203.06M | $241.05M | -33.3% |
| Total current assets | $115.23M | $175.66M | $207.41M | $247.01M | -34.4% |
| Property, plant & equipment | $1.04M | $1.55M | $19.05M | $20.49M | -33.1% |
| Total assets | $116.56M | $191.29M | $252.15M | $270.31M | -39.1% |
| Total current liabilities | $11.41M | $14.37M | $14.03M | $10.83M | -20.6% |
| Total debt | $838.00K | $1.19M | $13.29M | $13.98M | -29.6% |
| Total liabilities | $11.85M | $15.21M | $26.46M | $24.28M | -22.1% |
| Retained earnings | -$446.45M | -$368.71M | -$310.00M | -$241.04M | -21.1% |
| Shareholder equity | $104.71M | $176.08M | $225.69M | $246.03M | -40.5% |
| Working capital | $103.81M | $161.29M | $193.38M | $236.17M | -35.6% |
| Net tangible assets | $104.71M | $176.08M | $225.69M | $246.03M | -40.5% |
| Shares issued | 53.33M | 51.94M | 51.45M | 45.77M | +2.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -32.4% |
| Depreciation & amortisation | $133.00K | $1.14M | $1.26M | $315.00K | -88.4% |
| Stock-based compensation | $5.92M | $8.87M | $12.38M | $10.20M | -33.2% |
| Change in working capital | $914.00K | -$1.59M | $5.43M | -$568.00K | +157.4% |
| Operating cash flow | -$73.58M | -$51.28M | -$55.66M | -$63.76M | -43.5% |
| Capital expenditure | -$29.00K | -$655.00K | -$962.00K | -$7.98M | +95.6% |
| Investing cash flow | $70.17M | $53.35M | -$50.55M | -$1.37M | +31.5% |
| Financing cash flow | $505.00K | $313.00K | $35.58M | $958.00K | +61.3% |
| Free cash flow | -$73.61M | -$51.94M | -$56.62M | -$71.74M | -41.7% |
| End cash position | $37.98M | $40.88M | $38.53M | $109.12M | -7.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $14.68M | $15.33M | $15.83M | $18.21M | $18.40M | — | -4.3% |
| Selling, general & admin | $4.21M | $3.69M | $3.42M | $4.31M | $4.48M | — | +14.0% |
| Total operating expense | $18.88M | $19.02M | $19.24M | $22.52M | $22.88M | — | -0.7% |
| Operating income | -$18.88M | -$19.02M | -$19.24M | -$22.52M | -$22.88M | — | +0.7% |
| Net interest income | $788.00K | $980.00K | $1.23M | $1.48M | $1.69M | — | -19.6% |
| Pre-tax income | -$18.08M | -$18.04M | -$18.01M | -$21.07M | -$21.20M | — | -0.2% |
| Tax provision | $3.00K | $0 | $26.00K | -$6.00K | $5.00K | — | — |
| Net income | -$18.09M | -$18.04M | -$18.04M | -$21.06M | -$21.21M | — | -0.3% |
| Net income to common | -$18.09M | -$18.04M | -$18.04M | -$21.06M | -$21.21M | — | -0.3% |
| Basic EPS | -0.34 | -0.34 | — | -0.40 | -0.41 | -0.34 | 0.0% |
| Diluted EPS | -0.34 | -0.34 | — | -0.40 | -0.41 | -0.34 | 0.0% |
| EBIT | -$18.88M | -$19.02M | -$19.24M | -$22.52M | -$22.88M | — | +0.7% |
| EBITDA | -$18.86M | -$18.98M | -$19.21M | -$22.49M | -$22.85M | — | +0.7% |
| Basic shares | 53.39M | 53.33M | — | 52.99M | 52.01M | 51.95M | +0.1% |
| Diluted shares | 53.39M | 53.33M | — | 52.99M | 52.01M | 51.95M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.47M | $39.13M | $37.98M | $36.34M | $44.13M | -68.1% |
| Cash & short-term investments | $79.43M | $93.55M | $112.94M | $129.25M | $142.27M | -15.1% |
| Total current assets | $81.41M | $95.78M | $115.23M | $132.45M | $145.31M | -15.0% |
| Property, plant & equipment | $363.00K | $486.00K | $1.04M | $1.15M | $1.26M | -25.3% |
| Total assets | $82.07M | $96.56M | $116.56M | $133.84M | $152.85M | -15.0% |
| Total current liabilities | $10.57M | $8.60M | $11.41M | $12.30M | $11.61M | +23.0% |
| Total debt | $217.00K | $293.00K | $838.00K | $931.00K | $1.02M | -25.9% |
| Total liabilities | $10.57M | $8.60M | $11.85M | $12.85M | $12.25M | +23.0% |
| Retained earnings | -$482.58M | -$464.49M | -$446.45M | -$428.42M | -$407.36M | -3.9% |
| Shareholder equity | $71.50M | $87.97M | $104.71M | $121.00M | $140.60M | -18.7% |
| Working capital | $70.84M | $87.19M | $103.81M | $120.14M | $133.70M | -18.7% |
| Net tangible assets | $71.50M | $87.97M | $104.71M | $121.00M | $140.60M | -18.7% |
| Shares issued | 53.46M | 53.33M | 53.33M | 52.99M | 52.99M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$18.09M | -$18.04M | -$18.04M | -$21.06M | -$21.21M | — | -0.3% |
| Depreciation & amortisation | $24.00K | $34.00K | $33.00K | $31.00K | $32.00K | — | -29.4% |
| Stock-based compensation | $1.54M | $1.39M | $1.36M | $1.38M | $1.67M | — | +10.8% |
| Change in working capital | $2.30M | -$2.66M | $13.00K | $522.00K | $1.91M | — | +186.6% |
| Operating cash flow | -$14.58M | -$19.68M | -$17.19M | -$19.82M | -$18.30M | — | +25.9% |
| Capital expenditure | — | — | -$15.00K | — | -$11.00K | -$4.00K | — |
| Investing cash flow | -$12.23M | $20.82M | $18.44M | $12.03M | $10.99M | — | -158.7% |
| Financing cash flow | $143.00K | $0 | $392.00K | $0 | $103.00K | — | — |
| Free cash flow | -$14.58M | -$19.68M | -$17.20M | -$19.82M | -$18.31M | — | +25.9% |
| End cash position | $12.47M | $39.13M | $37.98M | $36.34M | $44.13M | — | -68.1% |
Options analytics
Put / call volume
4.00
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
+55.3% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
1
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
5.00
2 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.40 | -0.34 | +15.0% |
| Mar 2026 | -0.39 | -0.34 | +11.7% |
| Dec 2025 | -0.40 | -0.34 | +13.9% |
| Sep 2025 | -0.40 | -0.40 | +0.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.34 | 3 | $0 | 0.0% |
| Next quarter | -0.29 | 3 | $0 | 0.0% |
| Current year | -1.28 | 3 | $0 | 0.0% |
| Next year | -0.97 | 3 | $5.03M | 0.0% |
Analyst targets & ownership
Mean target$4.20
High target$5.00
Low target$3.00
Implied upside160.87%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders2.37%
Held by institutions46.43%
Institutions holding79
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.54
+4.38% from price
SMA 20
1.49
+7.93% from price
SMA 50
1.33
+20.60% from price
SMA 100
1.28
+25.98% from price
SMA 200
1.29
+24.80% from price
EMA 12
1.58
+2.17% from price
EMA 26
1.48
+9.03% from price
EMA 50
1.40
+15.34% from price
RSI (14)
58.3
Neutral
MACD (12,26,9)
0.10
Hist 0.03
ATR (14)
0.14
8.74% of price
Realised vol 30D
79.2%
Annualised
Bollinger upper
1.78
20, 2σ
Bollinger lower
1.20
20, 2σ
50 / 200 cross
Golden
1.33 vs 1.29
Trend bias
Above 200
+24.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
79.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.7%
Peak to trough
Max drawdown 5Y
-97.1%
Peak to trough
ATR 14
0.14
8.74% of price
Beta (reported)
1.35
5Y monthly, from filing
Short interest
Shares short
2.92M
Prior 2.24M
Change vs prior
+30.1%
Shorts adding
% of float
3.96%
Normal
% of shares out
3.87%
Against total outstanding
Days to cover
3.8
Liquid
Float
43.29M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 30, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 24 | Craig-Hallum | INITIATED | — | Buy |
| Apr 12, 24 | Jefferies | INITIATED | — | Buy |
| Mar 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 27, 23 | Ladenburg Thalmann | INITIATED | — | Buy |
| Oct 16, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 11, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEF 14A · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-03-06
Periodic Financial Reports
10-Q · 2025-11-12
Corporate Changes & Voting Matters
8-K · 2025-09-10
Headlines
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
GlobeNewswire · 2d ago
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
Simply Wall St. · 19d ago
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
Zacks · 21d ago
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
GlobeNewswire · 29d ago
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
Benzinga · 36d ago
Top Premarket Decliners
MT Newswires · 36d ago
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
GlobeNewswire · 36d ago
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
MT Newswires · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.